Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK2 | O95069 | 1/20 | 0.49 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.35 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15994581 | 0.98 | KCNK2 (0.48) | KCNK2KCNK10NPC1RAB9ASTING1 | |
| Hydrochloric Acid SCHEMBL21988903 | 0.98 | KCNK2 (0.48) | KCNK2KCNK10NPC1RAB9ASTING1 | |
| SCHEMBL16364784 | 0.93 | STING1 (0.43) | KCNK2KCNK10NPC1RAB9ASTING1 | |
| SCHEMBL30240184 | 0.93 | STING1 (0.43) | KCNK2KCNK10NPC1RAB9ASTING1 | |
| Hydrochloric Acid SCHEMBL16320375 | 0.91 | STING1 (0.43) | KCNK2KCNK10NPC1RAB9ASTING1 | |
| SCHEMBL17627488 | 0.85 | CTSV (0.42) | NPC1RAB9ASTING1MAPTKDM4E | |
| SCHEMBL22045554 | 0.79 | MAPT (0.46) | NPC1RAB9ASTING1MAPTKDM4E | |
| SCHEMBL24697741 | 0.78 | KEAP1 (0.45) | KCNK2KCNK10STING1CA1CA2 | |
| SCHEMBL29133155 | 0.78 | MAPT (0.45) | NPC1RAB9AAKR1C2AKR1C3MAPT | |
| Hydrochloric Acid SCHEMBL21988698 | 0.77 | MAPT (0.45) | NPC1RAB9ASTING1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382892-A1 | Chemical Compounds | PFIZER INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382892-A1 | Chemical Compounds | PFIZER INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-11702405-B2 | Chemical compounds | PFIZER INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702405-B2 | Chemical compounds | PFIZER INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11014908-B2 | Chemical compounds | PFIZER INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200172512-A1 | Chemical Compounds | PFIZER INC. (US) | 2020-06-04 | — | — | US | disclosed |
| WO-2020109994-A1 | PYRAZOLES AS MODULATORS OF HEMOGLOBIN | PFIZER INC. (US) | 2020-06-04 | — | — | WO | disclosed |
| US-20190152979-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2019-05-23 | — | — | US | disclosed |
| US-10221179-B2 | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors | DOMAIN THERAPEUTICS (FR) | 2019-03-05 | — | — | US | disclosed |
| EP-2961747-B1 | CARBAZOLE COMPOUNDS USEFUL AS BROMODOMAIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170305913-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2017-10-26 | — | — | US | disclosed |
| EP-3197897-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP IIMETABOTROPIC GLUTAMATE RECEPTORS | Domain Therapeutics (FR) | 2017-08-02 | — | — | EP | disclosed |
| US-20170152248-A1 | CARBAZOLE COMPOUNDS USEFUL AS BROMODOMAIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-06-01 | — | — | US | disclosed |
| WO-2016046404-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP IIMETABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2016-03-31 | — | — | WO | disclosed |
| EP-3000814-A1 | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors | Domain Therapeutics (FR) | 2016-03-30 | — | — | EP | disclosed |
| US-20160009701-A1 | CARBAZOLE COMPOUNDS USEFUL AS BROMODOMAIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-14 | — | — | US | disclosed |
| WO-2014134267-A1 | CARBAZOLE COMPOUNDS USEFUL AS BROMODOMAIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172512-A1 | Chemical Compounds | HBZ, HBB, HBS1L | KCNK2 1344/4885KCNK10 2572/4885NPC1 2812/4885 |
| US-11702405-B2 | Chemical compounds | HBZ, HBB, HBS1L | KCNK2 1344/4885KCNK10 2572/4885NPC1 2812/4885 |
| US-20160009701-A1 | CARBAZOLE COMPOUNDS USEFUL AS BROMODOMAIN INHIBITORS | BRD3, BRD4, BRPF3 | KCNK2 1854/4885KCNK10 2753/4885NPC1 434/4885 |
| US-10221179-B2 | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors | GRM1, GRM2, GRIN1 | KCNK2 560/4885KCNK10 1067/4885NPC1 3263/4885 |
| US-20230382892-A1 | Chemical Compounds | HBZ, HBB, HBS1L | KCNK2 1344/4885KCNK10 2572/4885NPC1 2812/4885 |
| US-20170305913-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | GRM1, GRM2, GRIN1 | KCNK2 560/4885KCNK10 1067/4885NPC1 3263/4885 |
| US-20170152248-A1 | CARBAZOLE COMPOUNDS USEFUL AS BROMODOMAIN INHIBITORS | BRD3, BRD4, BRPF3 | KCNK2 1854/4885KCNK10 2753/4885NPC1 434/4885 |
| US-11014908-B2 | Chemical compounds | HBZ, HBB, HBS1L | KCNK2 1344/4885KCNK10 2572/4885NPC1 2812/4885 |
| US-20190152979-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | GRM1, GRM2, GRIN1 | KCNK2 706/4885KCNK10 1253/4885NPC1 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.